AU2009324371B2 - Antibody formulation - Google Patents

Antibody formulation Download PDF

Info

Publication number
AU2009324371B2
AU2009324371B2 AU2009324371A AU2009324371A AU2009324371B2 AU 2009324371 B2 AU2009324371 B2 AU 2009324371B2 AU 2009324371 A AU2009324371 A AU 2009324371A AU 2009324371 A AU2009324371 A AU 2009324371A AU 2009324371 B2 AU2009324371 B2 AU 2009324371B2
Authority
AU
Australia
Prior art keywords
formulation
antibody
formulations
acz885
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009324371A
Other languages
English (en)
Other versions
AU2009324371A1 (en
Inventor
Joachim Momm
Hans-Joachim Wallny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009324371(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2009324371A1 publication Critical patent/AU2009324371A1/en
Application granted granted Critical
Publication of AU2009324371B2 publication Critical patent/AU2009324371B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2009324371A 2008-12-10 2009-12-09 Antibody formulation Active AU2009324371B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
EP08170884.4 2008-12-10
PCT/EP2009/066675 WO2010066762A1 (en) 2008-12-10 2009-12-09 Antibody formulation

Publications (2)

Publication Number Publication Date
AU2009324371A1 AU2009324371A1 (en) 2011-06-23
AU2009324371B2 true AU2009324371B2 (en) 2013-10-10

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009324371A Active AU2009324371B2 (en) 2008-12-10 2009-12-09 Antibody formulation

Country Status (31)

Country Link
US (3) US20110236398A1 (enExample)
EP (4) EP2196476A1 (enExample)
JP (5) JP6143416B2 (enExample)
KR (2) KR20170044211A (enExample)
CN (3) CN104399076B (enExample)
AU (1) AU2009324371B2 (enExample)
BR (1) BRPI0922730A2 (enExample)
CA (1) CA2745938C (enExample)
CL (1) CL2011001406A1 (enExample)
CO (1) CO6361952A2 (enExample)
CY (2) CY1117735T1 (enExample)
DK (2) DK2376533T3 (enExample)
EC (1) ECSP11011192A (enExample)
ES (2) ES2900624T3 (enExample)
HR (2) HRP20160754T1 (enExample)
HU (2) HUE028408T2 (enExample)
IL (3) IL264316B2 (enExample)
LT (1) LT3072906T (enExample)
MA (1) MA33023B1 (enExample)
MX (1) MX2011006242A (enExample)
MY (2) MY166050A (enExample)
NZ (1) NZ592918A (enExample)
PE (1) PE20120342A1 (enExample)
PL (2) PL2376533T3 (enExample)
PT (2) PT3072906T (enExample)
RU (2) RU2563179C2 (enExample)
SI (2) SI3072906T1 (enExample)
SM (1) SMT201600222B (enExample)
TN (1) TN2011000229A1 (enExample)
WO (1) WO2010066762A1 (enExample)
ZA (1) ZA201103362B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
KR101807894B1 (ko) 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
AU2011257219B2 (en) 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
FI2616090T3 (fi) 2010-09-17 2023-09-21 Baxalta GmbH Immunoglobuliinien stabilointi vesipitoisen histidiiniä sisältävän valmisteen avulla pH:ssa, joka on lievästi happamasta neutraaliin
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
PL3235508T3 (pl) 2011-03-16 2021-07-12 Sanofi Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3682905T3 (pl) 2011-10-03 2022-04-04 Modernatx, Inc. Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US10316095B2 (en) * 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
LT2825037T (lt) * 2012-03-16 2019-08-12 Regeneron Pharmaceuticals, Inc. Graužikai, ekspresuojantys ph jautrias imunoglobulino sekas
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
KR20220028177A (ko) * 2012-09-20 2022-03-08 모르포시스 아게 류마티스 관절염에 대한 치료
CA2891556A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
AR095496A1 (es) * 2013-03-15 2015-10-21 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
EP3148568A4 (en) * 2014-05-28 2018-01-17 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
CA2959571A1 (en) * 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
UA123270C2 (uk) * 2015-12-07 2021-03-10 Мерк Патент Гмбх Водний фармацевтичний препарат, який містить антитіло до pd-l1 авелумаб
SG11201810429UA (en) * 2016-06-27 2018-12-28 Morphosys Ag Anti-cd19 antibody formulations
KR20190032436A (ko) * 2016-07-21 2019-03-27 노파르티스 아게 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도
MA46334A (fr) * 2016-09-27 2019-08-07 Fresenius Kabi Deutschland Gmbh Composition pharmaceutique liquide
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
AU2018287519B2 (en) * 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019053591A1 (en) * 2017-09-13 2019-03-21 Novartis Ag USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS
MX2020009935A (es) * 2018-03-23 2021-01-08 Abbvie Deutschland Formulaciones acuosas y estables de anticuerpos anti-tau.
CA3100317A1 (en) 2018-05-17 2019-11-21 Astellas Pharma Inc. Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand
WO2020075746A1 (ja) * 2018-10-10 2020-04-16 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
CN113474360B (zh) * 2019-02-18 2025-01-07 伊莱利利公司 治疗性抗体制剂
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
CN114652825A (zh) * 2020-12-22 2022-06-24 百奥泰生物制药股份有限公司 稳定的抗体制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
BR0112026A (pt) * 2000-06-29 2003-05-20 Abbott Lab Anticorpos com dupla especificidade e métodos de produção e uso
WO2002011753A1 (en) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US20060210557A1 (en) * 2005-01-28 2006-09-21 Donna Luisi Stabilized liquid polypeptide formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20090110681A1 (en) * 2005-03-08 2009-04-30 Pfizer, Inc. Anti-M-CSF Antibody Compositions
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
CA2898369C (en) 2005-10-26 2017-06-20 Novartis Ag Novel use of il-1beta compounds
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
RU2009126420A (ru) * 2006-12-11 2011-01-20 Ф.Хоффманн-Ля Рош Аг (Ch) Парентеральная лекарственная форма антитела к абета
AU2008228823A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)
WO2003039485A2 (en) * 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies

Also Published As

Publication number Publication date
HRP20211899T1 (hr) 2022-03-04
CL2011001406A1 (es) 2012-03-30
MA33023B1 (fr) 2012-02-01
RU2745601C2 (ru) 2021-03-29
JP2020203889A (ja) 2020-12-24
TN2011000229A1 (en) 2012-12-17
ES2900624T3 (es) 2022-03-17
HK1159130A1 (zh) 2012-07-27
KR20170044211A (ko) 2017-04-24
US8623367B2 (en) 2014-01-07
RU2015132431A (ru) 2018-12-24
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
PT3072906T (pt) 2021-12-14
SMT201600222B (it) 2016-08-31
HUE056626T2 (hu) 2022-02-28
CN102245639B (zh) 2014-12-24
IL276622A (en) 2020-09-30
CA2745938A1 (en) 2010-06-17
CA2745938C (en) 2018-04-24
CN102245639A (zh) 2011-11-16
JP2012511540A (ja) 2012-05-24
JP2018168158A (ja) 2018-11-01
AU2009324371A1 (en) 2011-06-23
EP3072906B1 (en) 2021-09-08
IL264316B2 (en) 2024-01-01
BRPI0922730A2 (pt) 2018-11-06
HRP20160754T1 (hr) 2016-08-12
US20200384108A1 (en) 2020-12-10
CY1117735T1 (el) 2017-05-17
PE20120342A1 (es) 2012-04-24
MX2011006242A (es) 2011-06-24
MY166050A (en) 2018-05-22
CN104399076B (zh) 2021-09-14
EP2376533B1 (en) 2016-03-30
IL264316A (en) 2019-02-28
KR101762966B1 (ko) 2017-07-31
EP3792282A1 (en) 2021-03-17
PL2376533T3 (pl) 2016-09-30
US20120315285A1 (en) 2012-12-13
JP6143416B2 (ja) 2017-06-07
PT2376533T (pt) 2016-07-13
CO6361952A2 (es) 2012-01-20
CY1124844T1 (el) 2022-11-25
RU2011127913A (ru) 2013-01-20
RU2015132431A3 (enExample) 2018-12-24
DK2376533T3 (en) 2016-06-27
SI2376533T1 (sl) 2016-07-29
IL212922B (en) 2019-02-28
RU2563179C2 (ru) 2015-09-20
JP2023109938A (ja) 2023-08-08
ES2579835T3 (es) 2016-08-17
KR20120009421A (ko) 2012-01-31
JP2015231997A (ja) 2015-12-24
DK3072906T3 (da) 2021-12-13
EP2376533A1 (en) 2011-10-19
US20110236398A1 (en) 2011-09-29
LT3072906T (lt) 2021-12-27
EP2196476A1 (en) 2010-06-16
IL212922A0 (en) 2011-07-31
JP7286595B2 (ja) 2023-06-05
EP3072906A1 (en) 2016-09-28
PL3072906T3 (pl) 2022-01-24
ZA201103362B (en) 2012-01-25
IL264316B1 (en) 2023-09-01
HUE028408T2 (en) 2016-12-28
SI3072906T1 (sl) 2022-01-31
WO2010066762A1 (en) 2010-06-17
CN114225022A (zh) 2022-03-25
CN104399076A (zh) 2015-03-11
ECSP11011192A (es) 2011-08-31

Similar Documents

Publication Publication Date Title
AU2009324371B2 (en) Antibody formulation
EP1409018B1 (en) Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
JP2020063261A (ja) ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
US9833410B2 (en) Lyophilized formulation comprising GM-CSF neutralizing compound
KR20200014738A (ko) 안정한 항-osmr 항체 제형
US20030211103A1 (en) Use of primate IFN-gamma binding molecules
HK40041917A (en) Antibody formulation
JP2026021446A (ja) 抗体製剤
HK1159130B (en) Antibody formulation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)